205 related articles for article (PubMed ID: 35369397)
21. EZH2 Inhibition by Tazemetostat Results in Altered Dependency on B-cell Activation Signaling in DLBCL.
Brach D; Johnston-Blackwell D; Drew A; Lingaraj T; Motwani V; Warholic NM; Feldman I; Plescia C; Smith JJ; Copeland RA; Keilhack H; Chan-Penebre E; Knutson SK; Ribich SA; Raimondi A; Thomenius MJ
Mol Cancer Ther; 2017 Nov; 16(11):2586-2597. PubMed ID: 28835384
[TBL] [Abstract][Full Text] [Related]
22. Enhancer of zeste homolog 2 (EZH2) inhibitors.
Gulati N; Béguelin W; Giulino-Roth L
Leuk Lymphoma; 2018 Jul; 59(7):1574-1585. PubMed ID: 29473431
[TBL] [Abstract][Full Text] [Related]
23. Epigenetic Therapy for Epithelioid Sarcoma.
Rothbart SB; Baylin SB
Cell; 2020 Apr; 181(2):211. PubMed ID: 32302562
[TBL] [Abstract][Full Text] [Related]
24. No Significant Cytotoxic Effect of the EZH2 Inhibitor Tazemetostat (EPZ-6438) on Pediatric Glioma Cells with Wildtype Histone 3 or Mutated Histone 3.3.
Wiese M; Schill F; Sturm D; Pfister S; Hulleman E; Johnsen SA; Kramm CM
Klin Padiatr; 2016 Apr; 228(3):113-7. PubMed ID: 27135271
[TBL] [Abstract][Full Text] [Related]
25. First EZH2 Inhibitor Approved-for Rare Sarcoma.
Cancer Discov; 2020 Mar; 10(3):333-334. PubMed ID: 32041739
[TBL] [Abstract][Full Text] [Related]
26. Emerging EZH2 Inhibitors and Their Application in Lymphoma.
Lue JK; Amengual JE
Curr Hematol Malig Rep; 2018 Oct; 13(5):369-382. PubMed ID: 30112706
[TBL] [Abstract][Full Text] [Related]
27. Targeting epigenetics in sarcomas through EZH2 inhibition.
Italiano A
J Hematol Oncol; 2020 Apr; 13(1):33. PubMed ID: 32264965
[TBL] [Abstract][Full Text] [Related]
28. Initial testing (stage 1) of tazemetostat (EPZ-6438), a novel EZH2 inhibitor, by the Pediatric Preclinical Testing Program.
Kurmasheva RT; Sammons M; Favours E; Wu J; Kurmashev D; Cosmopoulos K; Keilhack H; Klaus CR; Houghton PJ; Smith MA
Pediatr Blood Cancer; 2017 Mar; 64(3):. PubMed ID: 27555605
[TBL] [Abstract][Full Text] [Related]
29. Early clinical and metabolic response to tazemetostat in advanced relapsed INI1 negative epithelioid sarcoma.
Tansir G; Rastogi S; Shamim SA; Barwad A
Future Sci OA; 2021 Jan; 7(4):FSO675. PubMed ID: 33815821
[TBL] [Abstract][Full Text] [Related]
30. Genetic and Epigenetic Characterization of Sarcoma Stem Cells Across Subtypes Identifies EZH2 as a Therapeutic Target.
O'Donnell E; Muñoz M; Davis R; Randall RL; Tepper C; Carr-Ascher J
bioRxiv; 2024 May; ():. PubMed ID: 38798385
[TBL] [Abstract][Full Text] [Related]
31. Positive Results for Tazemetostat in Follicular Lymphoma.
Cancer Discov; 2018 Aug; 8(8):OF3. PubMed ID: 29980507
[TBL] [Abstract][Full Text] [Related]
32. The Promise for Histone Methyltransferase Inhibitors for Epigenetic Therapy in Clinical Oncology: A Narrative Review.
Rugo HS; Jacobs I; Sharma S; Scappaticci F; Paul TA; Jensen-Pergakes K; Malouf GG
Adv Ther; 2020 Jul; 37(7):3059-3082. PubMed ID: 32445185
[TBL] [Abstract][Full Text] [Related]
33. When to Use Targeted Therapy for the Treatment of Follicular Lymphoma.
Nastoupil LJ
Curr Hematol Malig Rep; 2021 Feb; 16(1):45-51. PubMed ID: 33797691
[TBL] [Abstract][Full Text] [Related]
34. Epigenetic targeting of PGBD5-dependent DNA damage in SMARCB1-deficient sarcomas.
Kazansky Y; Mueller HS; Cameron D; Demarest P; Zaffaroni N; Arrighetti N; Zuco V; Mundi PS; Kuwahara Y; Somwar R; Qu R; Califano A; de Stanchina E; Dela Cruz FS; Kung AL; Gounder MM; Kentsis A
bioRxiv; 2024 May; ():. PubMed ID: 38766189
[TBL] [Abstract][Full Text] [Related]
35. Epigenetics of Indolent Lymphoma and How It Drives Novel Therapeutic Approaches-Focus on EZH2-Targeted Drugs.
Longley J; Johnson PWM
Curr Oncol Rep; 2021 May; 23(7):76. PubMed ID: 33937922
[TBL] [Abstract][Full Text] [Related]
36. A LYSA Phase Ib Study of Tazemetostat (EPZ-6438) plus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) with Poor Prognosis Features.
Sarkozy C; Morschhauser F; Dubois S; Molina T; Michot JM; Cullières-Dartigues P; Suttle B; Karlin L; Le Gouill S; Picquenot JM; Dubois R; Tilly H; Herbaux C; Jardin F; Salles G; Ribrag V
Clin Cancer Res; 2020 Jul; 26(13):3145-3153. PubMed ID: 32122924
[TBL] [Abstract][Full Text] [Related]
37. Overcoming clinical resistance to EZH2 inhibition using rational epigenetic combination therapy.
Kazansky Y; Cameron D; Mueller HS; Demarest P; Zaffaroni N; Arrighetti N; Zuco V; Kuwahara Y; Somwar R; Ladanyi M; Qu R; De Stanchina E; Dela Cruz FS; Kung AL; Gounder M; Kentsis A
bioRxiv; 2023 Dec; ():. PubMed ID: 36798379
[TBL] [Abstract][Full Text] [Related]
38. Integrase Interactor 1 (INI1) Deficiency in a Lung Cancer Patient Presents Nonresponse to Immunotherapy and Tazemetostat: A Case Report.
Chen X; Wu J; Pang G; Wei S; Wang P
Cureus; 2023 Aug; 15(8):e42934. PubMed ID: 37667707
[TBL] [Abstract][Full Text] [Related]
39. Recently discovered EZH2 and EHMT2 (G9a) inhibitors.
Soumyanarayanan U; Dymock BW
Future Med Chem; 2016 Sep; 8(13):1635-54. PubMed ID: 27548656
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of the Histone Methyltransferase EZH2 Enhances Protumor Monocyte Recruitment in Human Mesothelioma Spheroids.
Mola S; Pinton G; Erreni M; Corazzari M; De Andrea M; Grolla AA; Martini V; Moro L; Porta C
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33922336
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]